AGENDA: DUR BOARD MEETING  
Colorado Medicaid DUR  
Department of Health Care Policy and Financing

Skaggs School of Pharmacy and Pharmaceutical Sciences Building  
12850 East Montview Blvd, Aurora CO 80045  
Seminar Room- Room 1000; First floor  
Parking available in the Henderson/Visitor Parking Garage

May 16, 2017  
6:00 p.m. – 9:00 p.m. Open Session

DUR BOARD MEMBERS and CO DUR MEMBERS

<table>
<thead>
<tr>
<th>LeWayne Garrison, PharmD</th>
<th>Robert Lodge, PharmD (HCPF)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Karen Weber, DO</td>
<td>Robert L Page, PharmD, MSPH (CO DUR)</td>
</tr>
<tr>
<td>Sheila Botts, PharmD</td>
<td>Brandon Utter, PharmD (CO DUR)</td>
</tr>
<tr>
<td>Laura Borgelt, PharmD</td>
<td>Jon Campbell, PhD (CO DUR)</td>
</tr>
<tr>
<td>Alex Reish, DO</td>
<td>Garth Wright, MPH (CO DUR)</td>
</tr>
<tr>
<td>Caroline Kicklighter, PharmD</td>
<td>Gina Moore, PharmD (CO DUR)</td>
</tr>
<tr>
<td>Other members TBD</td>
<td></td>
</tr>
</tbody>
</table>

1. **Roll Call**

2. **Approval of the minutes from the February 21, 2017 meeting**

3. **Rules**

- Agenda items must be approved in advance, including requests to present information. Please contact Robert Lodge at (303) 866-3105 if you want to add an agenda item. Visitors are welcome during the open portion of the meeting only.
- Anyone wishing to provide testimony must contact the DUR Coordinator Robert Lodge (Robert.Lodge@state.co.us) at 303-866-3105 or at least 24 hours before the meeting.

Our mission is to improve health care access and outcomes for the people we serve while demonstrating sound stewardship of financial resources.  
www.colorado.gov/hcpf
4. **Open Session**

A. **Unfinished Business and General Orders**

- Approval of the minutes from the previous meeting
- Review Retro-DUR reports trending, some temporarily unavailable data from claims system transition
- Provider Education Reports
- Quarterly Drug Utilization Reports
- Module outlook summary
- FDA updates / New Drugs

*Update on the following:*

- Alzheimer’s agents (Neurocognitive disorder agents)
- Atypical antipsychotics
- Growth hormones
- Insulin
- Intranasal corticosteroids
- Leukotriene modifiers
- Multiple Sclerosis agents
- Ophthalmic allergy
- Sedative/hypnotics (non-benzodiazepine)
- Statins and Statin combinations

- Pulmozyme (dornase alfa)
- Emverm (mebendazole)
- Duexis (famotidine/ibuprofen)
- HP Acthar (corticotropin)

B. **New Business**

*Proposed Criteria for current PDL:*

- Antihistamines
- Antihypertensives
- Fibromyalgia agents
- Opioids – long acting
- Respiratory Inhalants
- Skeletal Muscle Relaxants
- Testosterone Products
- Topical Immunomodulators
Proposed Criteria for Other Agents:
- Acute pain opioids
- OTC drug coverage policies
- Austedo (deutetrabenazine)
- Dupixent (dupilumab)
- Ingrezza (valbenazine)
- Xyrem (sodium oxybate)
- Emflaza (deflazacort)
- Eucrisa (crisaborole)
- Kuvan (sapropterin dihydrochloride)
- Xiidra (lifitegrast)

5. Adjourn

Reasonable accommodations will be provided upon request for persons with disabilities. Please notify the Board Coordinator at 303-866-3105 or robert.lodge@state.co.us or the 504/ADA Coordinator hcpf504ada@state.co.us at least one week prior to the meeting to make arrangements.